NICE reviewed various technologies and recommended DERM as the only AI tool suitable for NHS use. It is the first dermatology ...

Lecanemab, currently licensed as a biweekly 10 mg/kg IV infusion, is developed by Eisai and Biogen to address the unmet needs of AD patients. AD, a chronic, progressive disease and the UK’s leading ...

Groundbreaking research has identified over 900 genetic links to osteoarthritis, including 500 previously undiscovered, in a ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for ...

Takeda has announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending European ...

Wilczewski CM, Obasohan J, Paschall JE, Zhang S, Singh S, Maxwell GL, Similuk M, Wolfsberg TG, Turner C, Biesecker LG, Katz ...

Argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) ...

It is not a one-time problem to solve but a constantly morphing puzzle with evolving guidelines, regional differences and ...

Women in Pharma founders reflect on their progress and ambitions ...

If you ask AI about the future of cancer care, it replies that it will ‘make cancer care more precise, proactive and ...

At the heart of this evolution are Smart Hospitals – facilities that harness advanced technologies to enhance patient care, ...

As we move into the second half of the decade, AI – particularly science-aware AI – seems destined to transform biopharma R&D ...